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Introduction {#sec005}
============

Lung cancer is the most prevalent cancer and leading cause of cancer-related deaths worldwide \[[@pone.0117333.ref001]\]. Despite improvements in therapeutic methodology, including surgery, chemotherapy and radiotherapy, the average prognosis of lung carcinoma still remains unsatisfactory and the five year survival rate is merely 15% \[[@pone.0117333.ref002]\]. Among those lung cancer patients, non-small cell lung cancer (NSCLC) accounted for approximately 80%-85% of lung cancer cases \[[@pone.0117333.ref003]\]. Conventionally, the clinical pathological stage is the important system for predicting the survival rate in patients \[[@pone.0117333.ref004]\]; the recent discovery of novel molecular signal alterations also may be involved in defining a therapy, which may turn out to be more effective and with less side effects than conventional treatment.

Increased attention has been garnered in the development and application of drugs that target specific molecules which expressed on NSCLC cells and great success has been reported in NSCLC patient study groups \[[@pone.0117333.ref005],[@pone.0117333.ref006]\]. These methods include signaling transduction and angiogenesis inhibitors, such as the epidermal growth factor receptor (*EGFR*) targeted drugs \[[@pone.0117333.ref007]\]. Therefore, the identification of the key ontogeny for cancer was a critical step in developing molecular-targeting agents.

In the year 2007, the fusion of echinoderm microtubule-associated protein-like 4 (*EML4*) genes with anaplastic lymphoma kinase (*ALK*) was found in lung cancer \[[@pone.0117333.ref008]\]. The fusion of the N-terminal half of *EML4* and the intracellular kinase domain of *ALK* within chromosome 2p lead to expression of chimeric tyrosine kinase \[[@pone.0117333.ref009]\]. The *EML4-ALK* fusion gene possessed potent critical biological activity in vitro and in vivo, such as cell proliferation, apoptosis and metastasis \[[@pone.0117333.ref010]\], which can be effectively blocked by the *ALK* kinase inhibitor (Crizotinib) \[[@pone.0117333.ref011]\], which lends a supporting role for the *EML4-ALK* fusion gene in lung tumorigenesis. To identify patients likely to benefit from Crizotinib, it is necessary to develop a robust and effective diagnostic algorithm to detect the *EML4-ALK* fusion gene when screening patients for treatment with Crizotinib. Currently, the following three methodologies are used to detect the *EML4-AL*K fusion gene, which include: fluorescence in situ hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical (IHC). However, the best algorithm for screening the *EML4-ALK* fusion gene in clinical lung cancer populations remains to be determined, since the three methodologies described above have different advantages and disadvantages. To improve the detection efficiency of the three methodologies, we investigated if combining the clinicopathological characteristics of NSCLC with the *EML4-ALK* fusion gene would yield useful information for the effective pre-screening of patients with the *EML4-ALK* fusion gene in clinical practice.

Despite a large number of studies on patients harboring the *EML4-ALK* fusion gene demonstrating unique clinical physiological and pathological characteristics \[[@pone.0117333.ref012]\], detailed clinicopathological profiles remain unclear because of the small number of cases identified. To correlate the *EML4-ALK* fusion gene with the NSCLC profile (including smoking status, gender, tumor types, stage and ethnic characteristics) and ascertain the relationship of *EML4-ALK* with *EGFR* and *KRAS* mutations, we performed the present meta-analysis of 6950 patients from 27 studies.

Methods {#sec006}
=======

Search Strategy {#sec007}
---------------

Electronic searches were performed until April 2014 and included various sources, such as MEDLINE, Embase Databases, Elsevier Science Direct, ISI Web of Science, China National Knowledge Internet, China Biology Medical Literature Database, and the Database of Chinese Scientific and Technical Periodicals. No language restrictions were applied. The keywords were as follows: "non-small cell lung cancer or NSCLC", "echinoderm microtubule-associated protein-like 4 or *EML4*", "anaplastic lymphoma kinase or *ALK*", "fusion gene", "physiological and pathological characteristics". We searched the reference lists of relevant reviews, editorials, studies, meeting abstracts and letters. We used the Sciences Citation Index to cross reference for further studies that fulfilled the eligibility criteria.

Study selection {#sec008}
---------------

The studies included in this meta-analysis according to our predetermined criteria are as follows: (1) the trials that include the full text of the paper published in peer-reviewed English and Chinese journals or reports of presentations at major oncology meetings; (2) evaluation of the associations between the *EML4-ALK* fusion gene and clinicopathological characteristics in NSCLC patients; (3) similarity in the patients'baseline characteristics.

Data extraction and quality assessment {#sec009}
--------------------------------------

Two reviewers (Zhao and Lei) independently collected the data with the standard protocol. The following criteria were set to screen the articles which were eligible for our study: (1) expression of the *EML4-ALK* fusion gene was evaluated in primary lung cancer tissue as opposed to metastatic tissue; (2) methods used to detect the *EML4-ALK* fusion gene expression, including IHC, FISH or RT-PCR; (3) the histological type of the tumors was NSCLC; (4) comparison of the risk ratio (RR) and its confidence interval (CI) between patients who harbor the *EML4-ALK* fusion gene over expression and the counterparts were described or statistically extractable from the data in the article; (5) when multiple articles were published by the same authors or groups, the most informative or newest single article was selected. The studies were evaluated with the Downs and Black quality assessment method\[[@pone.0117333.ref013]\]; (6) potential disagreements were resolved by discussion and consensus with senior investigator (Xu).

Statistical and Sensitivity Analysis {#sec010}
------------------------------------

This meta-analysis was performed in the RevMan 5.2 software. Statistical calculations were used with SPSS (version 17.0 SPSS Inc., IL, USA). The relative risk (RR) and the mean difference with 95% confidence intervals (95% CI) were calculated for the continuous outcomes and dichotomous outcomes, respectively. P\<0.05 was considered as a significant difference in the value between the two groups. The I^2^ statistic was used to investigate the heterogeneity among the studies. The heterogeneity was explored by I^2^ and χ^2^, I^2^\<50% indicated a small inconsistency and I^2^\>50% indicated a large inconsistency. When there was a statistical difference in terms of the heterogeneity (I^2^\>50%), the random-effect model was used to pool the data; Otherwise, a fixed-effect model was selected.

Publication bias {#sec011}
----------------

For publication bias estimating, we can visually observe any significant statistically symmetrical differences, according to the funnel plot.

Results {#sec012}
=======

Description of the Studies {#sec013}
--------------------------

27 retrospective cohort studies coincided with our criteria and are included in this meta-analysis. A total of 6950 patients were included in the 27 studies, among which 24 (5130 cases) estimated the association of fusion of the *EML4-ALK* gene in NSCLC with a history of smoking; while 17 studies emphasized the association of the *EML4-ALK* rearrangement to tissue types (3360 cases); 13 papers reflected the relation of the *EML4-ALK* fusion gene to clinical stages (2876 cases) and 26 researches showed the association of this fusion gene and the gender of patients (5797 cases). To search algorithm, the results of the selection criteria and search strategies are shown in [Fig. 1](#pone.0117333.g001){ref-type="fig"}, and the characteristics of patients and detected methods of the *EML4-ALK* fusion gene are shown in [Table 1](#pone.0117333.t001){ref-type="table"}.

![Flow diagram of study selection.](pone.0117333.g001){#pone.0117333.g001}

10.1371/journal.pone.0117333.t001

###### Characteristics of included studies regarding patients and detected methods.

![](pone.0117333.t001){#pone.0117333.t001g}

  **Author(ref.)**                         **Year**   **Total**   **Gender**   **Smoking**   **Pathological Type**   **TMN(stage)**   **methods**                                     
  ---------------------------------------- ---------- ----------- ------------ ------------- ----------------------- ---------------- ------------- ------ ------ ------ ------ ----- -------------------
  Inamura K \[[@pone.0117333.ref014]\]     2008       221         80           69            65                      84               149           72     63     85a    \-     \-    RT-PCR
  Soda M\[[@pone.0117333.ref015]\]         2007       75          22           11            9                       24               18            15     \-     \-     \-     \-    RT-PCR
  Shinmura K\[[@pone.0117333.ref016]\]     2008       77          39           38            41                      22               50            27     \-     \-     \-     \-    RT-PCR
  Kentaro I\[[@pone.0117333.ref017]\]      2008       253         134          119           142                     110              \-            \-     \-     \-     \-     \-    RT-PCR
  Shaw AT \[[@pone.0117333.ref018]\]       2009       141         48           93            59                      82               89            52     25     1      9      96    FISH
  Wong DW \[[@pone.0117333.ref019]\]       2009       266         132          134           141                     125              209           57     153    47     60     6     RT-PCR
  Inamura K \[[@pone.0117333.ref020]\]     2009       363         134          119           105                     147              253           110    143    110a   \-     \-    RT-PCR, FISH
  Martelli MP \[[@pone.0117333.ref021]\]   2009       120         96           24            16                      101              63            57     65     21     22     11    RT-PCR
  Rodig SJ\[[@pone.0117333.ref022]\]       2009       358         138          220           85                      243              358           0      169    29     67     93    FISH, IHC
  Jokoji R \[[@pone.0117333.ref023]\]      2010       254         130          124           51                      84               \-            \-     \-     \-     \-     \-    IHC
  TakahashiT \[[@pone.0117333.ref024]\]    2010       313         111          100           92                      119              211           102    141    20     42     8     RT-PCR
  Zhang X \[[@pone.0117333.ref025]\]       2010       103         74           29            52                      51               62            41     63     18     20     2     RT-PCR
  Sanders HR \[[@pone.0117333.ref026]\]    2011       55          \-           \-            \-                      \-               37            18     \-     \-     \-     \-    RT-PCR
  Shaw AT \[[@pone.0117333.ref027]\]       2011       411         177          234           175                     237              377           35     \-     \-     \-     \-    FISH
  Sequist LV \[[@pone.0117333.ref028]\]    2011       546         228          318           128                     415              440           106    165    32     105    241   RT-PCR
  Jin G \[[@pone.0117333.ref029]\]         2012       167         85           82            73                      94               121           46     93     74     \-     \-    RT-PCR
  Kim HR \[[@pone.0117333.ref030]\]        2012       229         30           199           \-                      \-               215           14     43     31     61     94    FISH,
  Koivunen JP \[[@pone.0117333.ref031]\]   2012       305         187          204           69                      184              208           97     183    59     50     9     RT-PCR
  Lin XM \[[@pone.0117333.ref032]\]        2012       102         54           48            73                      29               73            29     34     17     40     11    RT-PCR
  Han XH\[[@pone.0117333.ref033]\]         2013       137         56           81            107                     32               135           4      \-     \-     27     112   RT-PCR, FISH, IHC
  Takamochi k \[[@pone.0117333.ref034]\]   2013       222         117          105           101                     120              \-            \-     150    71a    \-     \-    RT-PCR, FISH, IHC
  Zhang YG \[[@pone.0117333.ref035]\]      2013       473         314          159           180                     293              341           132    166    209b   \-     98    RT-PCR, FISH, IHC
  Fang P\[[@pone.0117333.ref036]\]         2013       60          34           26            35                      25               \-            \-     16     16     18     10    FISH
  Zhong S \[[@pone.0117333.ref037]\]       2013       268         183          85            118                     123              132           79     \-     \-     \-     \-    RT-PCR
  Wang M \[[@pone.0117333.ref038]\]        2013       245         178          67            118                     127              114           131    62     113    40     30    IHC
  Li Y\[[@pone.0117333.ref039]\]           2013       208         147          61            78                      130              95            113    49     43     106    10    RT-PCR
  Yang JJ\[[@pone.0117333.ref040]\]        2014       977         182          212           308                     86               377           17     75c    \-     319d   \-    RT-PCR, FISH, IHC
  Total                                               6950        3238         2734          2035                    2871             3655          1224   1734   404    561    821   \-

M:male; F:female AD: adenocarcinom; NAD: non-adenocarcinoma; a.Patients of stage II-IV; b. Patients of stage II-IIIA; c. Patients of stage I-II; d. Patients of stage III-IV; RT-PCR: real-time polymerase chain reaction; IHC: immunohistochemestry; FISH: fluorescence in situ hybridization.

Direct meta-analysis and pooled outcomes {#sec014}
----------------------------------------

Meta-analysis of the literature revealed 27 publications, which included 6950 NSCLC patients; 472 of these patients (6.8%) harbored the *EML4-ALK* fusion gene. 24 studies out of 27 documented the correlation between smoking history and the *EML4-ALK* fusion gene. We detected no significant bias between the two groups (P = 0.16 I^2^ = 23%) when the fixed effects model was used. The combined result is shown in [Fig. 2A](#pone.0117333.g002){ref-type="fig"}. Compared with smoking cases, non-smokers with NSCLC have a statistically significant higher risk in the presence of the *EML4-ALK* fusion gene (12.6% vs 3.4%, RR = 3.41, 95%CI, 2.72--4.27, *P*\<0.01). 17 studies assessed the *EML4-ALK* fusion gene in adenocarcinoma and non-adenocarcinoma groups, and heterogeneity was indentified through the 16 reports (*P* = 0.26 I^2^ = 17%). Then data were analyzed using a fixed effects model. The results indicated that the *EML4-ALK* fusion frequency is higher in the adenocarcinoma group than in the non-adenocarcinoma group (11.2% vs 3.3%, RR = 2.30, 95%CI, 1.60--3.31, *P*\<0.01) in [Fig. 2B](#pone.0117333.g002){ref-type="fig"}. 13 studies expressed the association between tumor stage and the *EML4-ALK* fusion gene. There is no significant bias between stage I-II and stage III-IV (*P* = 0.57 I^2^ = 0%); therefore, data were analyzed using a fixed effects model. Our results suggest that there was a statistically significant increase in the frequency of *EML4-ALK* mutations in stage III-IV than in stage I-II (8.2% vs 4.0%, RR = 0.52, 95%CI, 0.38--0.72, *P*\<0.01) in [Fig. 2C](#pone.0117333.g002){ref-type="fig"}. In addition, 26 out of these 27 studies documented the *EML4-ALK* fusion in female and male groups. We detected no significant bias between the two groups (*P* = 0.08 *I^2^* = 30%) and analyzed the data using a fixed effects model. Our results suggest that there was no significant difference between the male and female groups. (7.6% versus 6.3%, RR = 1.06, 95%CI, 0.89--1.27, p = 0.52) in [Fig. 2D](#pone.0117333.g002){ref-type="fig"}.

![Meta-analysis of data for EML4-ALK.\
(A smokers vs no-smokers; B adenocarcinomas vs non-adenocarcinomas; C stages I-II vs stages III-IV; D male vs female). Forest plot of the Relative Risk (RR) of the clinicopathological characteristics with *EML4-ALK* fusion gene patients. The RR estimate of each individual trial corresponds to the middle of the squares and the horizontal line gives the 95% CI. On each line, the numbers of events are represented as fractions of the total number; random choices are shown for both treatment groups. For each subgroup, the sum of the statistics, along with the summary RR are represented by the middle of the solid diamonds. A test of heterogeneity between the trials within a subgroup is given below in summary of the statistics.](pone.0117333.g002){#pone.0117333.g002}

We also extended our study to perform three methods (FISH, RT-PCR and IHC) for direct comparison of sensitivity and specificity. Among the 3,813 patients included for the FISH study, 336 patients (8.8%,) were found to have the *EML4-ALK* rearrangement. Among the 5,236 patients, 280 (5.3%) were significantly positive by detection of RT-PCR. A total of 2,688 patients had successful IHC staining detection of the *EML4-ALK* fusion expression and 191 patients harbored the *EML4-ALK* fusion gene (7.1%) in [Table 2](#pone.0117333.t002){ref-type="table"}.

10.1371/journal.pone.0117333.t002

###### The detecting methods of the *EML4-ALK* fusion gen.

![](pone.0117333.t002){#pone.0117333.t002g}

  **Methods**   ***ELM4-ALK* fusion**   **Total**      
  ------------- ----------------------- -------------- -------
  FISH          336(8.8%)               3,477(91.2%)   3,813
  RT-PCR        280(5.3%)               4,956(94.7%)   5,236
  IHC           191(7.1%)               2,477(92.9%)   2,668

The χ2 test indicate there was significant difference among the three diversified methods in the diagnostic detection rate of EML4-ALK fusion gene (χ2 = 21.04, p = 0.000).

In this analysis, 27 studies evaluated the *EML4-ALK* fusion gene in different ethnicity groups. The difference of fusion rates in Asian and non-Asian population was significant; there were 6,950 patients selected from 27 randomized trials, 4906 in Asian and 2,044 from non-Asian populations. Patients in non-Asian ethnicity groups had a higher mutation rate than those in Asian ethnicity groups (8.5% versus 6.1% χ^2^ = 12.80 P = 0.00) in [Table 3](#pone.0117333.t003){ref-type="table"}.

10.1371/journal.pone.0117333.t003

###### Comparison of EML4-ALK mutation rate between Asian and non-Asian.

![](pone.0117333.t003){#pone.0117333.t003g}

  **Group**    ***EML4-ALK* fusion**   **Total**      
  ------------ ----------------------- -------------- -------
  Asian        299(6.1%)               4,607(93.9%)   4,906
  non- Asian   173(8.5%)               1,871(91.5%)   2,044
  Total        472(6.8%)               6,478(93.2%)   6,950

The χ2 test indicated that the rate of ALK mutation in non-Asian group was statistically higher than the Asian group (χ2 = 12.8, p = 0.000).

There were 694 patients with *EGFR* mutations and 107 patients with *KRAS* mutations. Additionally, there were 214 patients with the *EML4-ALK* fusion gene, as summarized in [Table 4](#pone.0117333.t004){ref-type="table"}. 199 patients who harbor the *EML4-ALK* fusion gene had wild-type *EGFR* and *KRAS*. Statistical analysis demonstrated a significant association of the *EML4-ALK* fusion gene with wild-type *EGFR* (*P* = 0.00 McNemar test) and *KRAS* (*P* = 0.00 McNemar test). Nevertheless, we identified 15 *EML4-ALK* fusion NSCLC patients in our study that showed coexistent mutations in *EGFR* in [Table 4](#pone.0117333.t004){ref-type="table"}.

10.1371/journal.pone.0117333.t004

###### The correlation with ALK fusion mutation and EGFR/KRAS mutation.

![](pone.0117333.t004){#pone.0117333.t004g}

  **Group**   **EGFR**     **Total**      **KRAS**     **Total**                            
  ----------- ------------ -------------- ------------ ----------- ------------ ----------- ----
  EML4-ALK    (+)          15(2.1%)       146(97.9%)   161         0(0%)        53 (100%)   53
  (-)         679(12.1%)   1,059(87.9%)   1,738        107(8.3%)   588(91.7%)   695         

The McNemar test illustrated that there was a statistically significant difference in the case number between *EML4-ALK* fusion and *EGFR* mutation (p = 0.000), the outcome of *KRAS* followed the same pattern (p = 0.000).

Publication Bias {#sec015}
----------------

Publication bias can exist when non-significant findings remain unpublished. Begg's funnel plot was performed to assess the potential publication bias in all literature. As shown in [Fig. 3](#pone.0117333.g003){ref-type="fig"}, the symmetric shape of funnel plots does not reveal any evidence of publication bias.

![Funnel plot of the outcome of clinicopathological characteristics and the EML4-ALK fusion gene.\
(smokers vs non-smokers; B adenocarcinomas vs non-adenocarcinomas; C stages I-II vs stages III-IV; D male vs female).](pone.0117333.g003){#pone.0117333.g003}

Discussion {#sec016}
==========

According to tumor-specific biological characteristics, molecularly targeted therapies recently showed a new strategy that demonstrated the importance of small subgroup patients. The *EML4-ALK* fusion gene represents a new subgroup of NSCLC patients who respond positively to ALK inhibitors \[[@pone.0117333.ref011]\].

Presently, the most comprehensive meta-analysis regarding the clinical characteristics of the *EML4-ALK* fusion gene was done in our study. We fully analyzed 6,950 cases from 27 articles. Our findings showed a low incidence (6.8%) of the *EML4-ALK* translocation among unselected NSCLC patients; this proved consistent with previous reports (1.4%\~11.6%) \[[@pone.0117333.ref016],[@pone.0117333.ref017],[@pone.0117333.ref020]\]. Since the incidence of *EML4-ALK* is low in NSCLC patients, it is necessary to elucidate clinicopathological characteristics of the *EML4-ALK* fusion gene-positive lung cancer to improve screening efficiency. Our results indicated that the *EML4-ALK* fusion gene occurred predominantly in non-smoking, adenocarcinoma patients, although no statistical difference was found between male and female patients. The likely interpretation of this phenomenon is that adenocarcinoma account for a major portion of the female patients who seldom smoke. The findings above showed that *EML4-ALK* fusion gene-related carcinogenesis might be different from chronic inflammation induced by smoking or tuberculosis \[[@pone.0117333.ref041]\]. Therefore, we believe that clinical characteristics, such as smoking status, and adenocarcinoma, should be used to select patients for *EML4-ALK* fusion gene screening.

Meanwhile, we found that the incidence of EML4-ALK fusion III-IV patients was slightly higher than that in stage I-II patients. We suggest that the NSCLC patients should be finished *EML4-ALK* fusion detection before ALK molecular inhibitor treatment. In addition, this unbalanced stage distribution could have been due to the availability of fresh frozen tissues for RT-PCR, which is more likely in operable patients (stage I and III), but difficult for stage II and IV patients. However, the incidences of *EML4-ALK* rearrangements in stage III patients were higher than in the other stages \[[@pone.0117333.ref025],[@pone.0117333.ref042],[@pone.0117333.ref043]\]. In Takamochi's study, the proportion of lymph node involvement in *EML4-ALK* fusion gene-positive adenocarcinoma was significantly more frequent than in the negative counterpart \[[@pone.0117333.ref034]\]. According to Paik's report, *EML4-ALK* fusion gene-positive adenocarcinomas may metastasize to lymph nodes \[[@pone.0117333.ref044]\], and Vincent reported that *EML4-ALK* fusion gene-positive tumors tend to have lymph node and brain metastases \[[@pone.0117333.ref045]\]. All findings stated above were potentially involved in determining why the fusion gene was more frequently seen in the advanced NSCLC.

Currently, several methodologies are used to detect *EML4-ALK* fusion, including FISH, RT-PCR and IHC. In our meta-analysis, the positive rate of FISH, RT-PCR and IHC was 8.8%, 5.3% and 7.1% respectively. An accurate and reliable method for the detection of *EML4-ALK* fusion is crucial for selecting NSCLC patients who are candidates for treatment with *ALK* inhibitors. Although FISH assay has been used to identify patients with the *EML4-ALK* fusion gene in clinical trials, a gold standard method to determine the *EML4-ALK* fusion gene has not been established. Our investigation revealed that the popular methods used to detect the *EML4-ALK* fusion gene are FISH and RT-PCR. Theoretically, RT-PCR and FISH are two approaches for detecting genes fusion; however, both have considerable limitations in clinical practice. RT-PCR required fresh tissue samples for RNA extraction and a reliable FISH assay required a good fluorescence scope and technical expertise. IHC for testing *EML4-ALK* fusion is a well-established method, particularly since the cost of IHC is much lower than that of FISH. So IHC could be a much more convenient and cost-effective screening method for the *EML4-ALK* fusion gene in NSCLC patients \[[@pone.0117333.ref041]\]. However, because RT-PCR methodology may not identify novel rearrangements involving previously uncharacterized EML4-ALK variants or unknown fusion partners and its process may be readily contaminated, its sensitivity and specificity remain to be validated \[[@pone.0117333.ref035]\]. IHC has the strengths of being widely available, relatively easy to perform and retains morphological information, which allows confident assessment of aberrant genes in tumor cells. Several ALK antibodies, reported in recent studies, shows that IHC has high concordance with FISH. Thus, these results suggested that in routine practice, IHC assay is a tool of value for the prescreening of patients with ALK fusion gene in clinical practice, and FISH assay can be performed as a confirmation method. This is consistent with previous reports \[[@pone.0117333.ref034],[@pone.0117333.ref035],[@pone.0117333.ref046]\].

It should be noted, that for first time in our studies, we determined that the *EML4-ALK* fusion gene appeared more frequently in non-Asian patients, as opposed to their Asian counterparts; this means that the prevalence of *EML4-ALK* fusion in the non-Asian population is higher than that in other ethnicities. This result indicates that the *EML4-ALK* fusion may be linked to non-Asian ethnicity, as opposed to *EGFR* mutations, which are linked to Asians. Wu recently reported that among NSCLC patients with available date on ethnicity and variant type data for the *EML4-ALK* fusion gene, variant 3(52.3%) was the most common type in the Chinese population, while variant 1(75.7%) was most common in the Caucasian population \[[@pone.0117333.ref047]\]. These results further indicated that the prevalence of the *EML4-ALK* fusion gene may vary amongst different ethnic groups.

Although *EML4-ALK* fusion and *EGFR* mutations were previously reported to be mutually exclusive, several studies have shown that *EML4-ALK* rearrangements can occur concurrently with *EGFR* mutations \[[@pone.0117333.ref048],[@pone.0117333.ref049]\]; however, these may be rare events. Our data demonstrated that there are 15(15/6950) patients who harbored concomitant *EML4-ALK* fusion and *EGFR* mutations. In addition, comparison of *EML4-ALK* rearrangement with the *KRAS* mutations in the same NSCLC samples revealed that the *EML4-ALK* fusion gene was mutually exclusive of the *KRAS* mutations. Therefore, a stepwise mode to select for gene mutations in NSCLC is suggested: first for *KRAS*, second for *EGFR*, *EML4-ALK* translocation, and then for concomitant *EML4-ALK* fusion and *EGFR* mutations. If a patient is positive for a *KRAS* mutation, no further molecular testing will be required. The treatment approach will focus on chemotherapy, as tumors with somatic mutations in *KRAS*, which encodes a GTPase downstream of *EGFR*, exhibit greater resistance to the targeted drugs. If the patient is negative for *KRAS* mutations, it will be necessary to screen for *EGFR* mutations and the *EML4-ALK* fusion gene. A positive result for either will indicate molecular treatment using *EGFR* tyrosine kinase inhibitors (TKI) or *ALK* inhibitor. When patients harbor concomitant *EML4-ALK* fusion and *EGFR* mutations, treatment strategies may be helpful, since this subgroup has a specific genotype with dual therapeutical targets. As Yang's report \[[@pone.0117333.ref040]\], testing of the relative phosphorylation levels of *EML4-ALK* and *EGFR* might help to guide the selection of *ALK* inhibitor or *EGFR*-TKIs in clinical practice.

Conclusion {#sec017}
==========

Our analysis indicated that *EML4-ALK*-positive NSCLC comprised a unique subgroup of adenocarcinomas with distinct clinicopathological characteristics. We also concluded that *EML4-ALK* fusion was mutually exclusive of EGFR mutation *KRAS* mutations. Compared with non-*EML4-ALK*-positive NSCLC, this group is significantly enriched for non-smoking patients with adenocarcinoma. The positive rate of the *EML4-ALK* fusion gene expression in females was slightly higher than that in males, but not significantly. These patients typically present in late stages, which is not amenable for surgical resection. Therefore, the molecular target regimens that target the *EML4-ALK* fusion protein would be an effective, novel therapeutic method for them. Our studies represent *EML4-ALK* fusion based on the unique clinicopathological characteristics. In addition, HC assay is a tool of value for the prescreening of patients with ALK fusion gene in clinical practice, and FISH assay can be performed as a confirmation method.
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